Today: Fri 31 Oct 2014
Register & Login:  Register
   Login
Register Login

cardiovascular risk

The following articles have the tag cardiovascular risk

Statin stop: the Catalyst effect

UP TO 40% of patients who told their doctor they were concerned about the recent ABC Catalyst program had already stopped taking their statins, a small survey of GPs shows. PLUS AUDIO: Dr Joe Kosterich on patients quitting statins.

Older NSAIDs raise vascular risks

THE magnitude of cardiovascular risk among people taking NSAIDs has been quantified in a new meta-analysis.

Fast Forward - 23 October 2012

Fast Forward - 23 October 2012

MO looks back 10 years, casting a fresh eye over what made the news in 2002. Then we hit the fast-forward button to see what’s changed.

Cardiovascular risk doubles with earlier menopause

WOMEN who experience early menopause – either surgically induced or natural – have double the risk of a cardiovascular event compared to other women, research has found.

Aspirin neuroprotective in elderly women at high CV risk

LOW-dose aspirin may slow cognitive decline, at least in elderly women at increased risk for cardiovascular events, research suggests.

Diabetes drugs linked to increased CV risk

THE TGA is considering whether additional precautions are warranted for a number of the sulfonylureas within the class of insulin secretagogues, following a study suggesting they are associated with increased mortality and cardiovascular risk. A TGA spokesperson said findings from the European Heart Journal study, comparing insulin secretagogue monotherapy with metformin, were being reviewed. The Danish authors followed more than 100,000 subjects who had received insulin secretagogues or metformin for nine years. They found increased all-cause mortality, cardiovascular death, and a composite of myocardial infarction, stroke and cardiovascular death, associated with all of the ...

Least harmful NSAID for cardiovascular patients identified

THE safety of NSAIDs is back in the news, following a meta-analysis showing little evidence they are safe for patients at high cardiovascular risk. However, the researchers said that of the seven NSAIDs examined, naproxen appeared the least harmful. “In general, naproxen seems to be the safest analgesic for patients with osteoarthritis in cardiovascular terms,” the authors wrote. However, naproxen’s relative benefits should be weighed against the drug’s gastrointestinal toxicity and the need for concomitant use of proton pump inhibitors, they warned. Celecoxib 400 mg prescribed once daily may be considered an alternative, they said. ...

Delay of rosiglitazone study puts heat on FDA

CONTROVERSY over the continued use of rosiglitazone has flared again, following allegations that the US Food and Drug Administration (FDA) is sitting on  a new study into the drug’s side-effects. The draft manuscript, posted online by the US Pharmalot blog, purports to show that rosiglitazone increased the risk of stroke, heart failure and death compared with pioglitazone, concluding it should be taken off the market. Lead author Dr David Graham, an FDA epidemiologist, emailed the FDA commissioner late in May to inform her the study was ready for publication but was being delayed by his supervisor. ...

Crunch time for eating nuts after lipid-lowering findings

Crunch time for eating nuts after lipid-lowering findings

EATING nuts can substantially reduce cholesterol levels and could offer a cheap and effective strategy for reducing cardiovascular risk. Spanish researchers have found that eating just 67 g of nuts a day reduced total cholesterol levels by 5.1% and LDL cholesterol by 7.4 per cent.

Fibrates found to offer CVD protection

THE uncertainty surrounding the role of fibrates in the prevention of cardiovascular disease may be a step closer to being clarified as Australian experts find that fibrates significantly reduce the risk of cardiovascular events. Their review and meta-analysis of 18 trials found use of fibrates led to a 10% reduction in major cardiovascular events and a 13% reduction in coronary events. Fibrates also reduced the risk of albuminuria progression by 14% and were not associated with a significant increase in drug-related adverse events.  There was no reduction in stroke however, and no statistically significant effect on ...

TGA to review rosiglitazone safety

THE TGA is set to re-examine the safety of rosiglitazone, following a US senate report that has raised new fears about the drug’s cardiovascular risk. The report, released on Saturday, marked the conclusion of a two-year inquiry by the US Committee on Finance, which included a review of internal documents from the drug’s manufacturer GlaxoSmithKline (GSK). Senators accused GSK of downplaying findings that rosiglitazone might increase cardiovascular risk and failing to sufficiently warn patients and regulators. A spokeswoman said the TGA was reviewing the report and awaiting a response ...

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement